# Medicxi

Source: https://onco.cc/companies/medicxi/  
OnCo record `medicxi` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A London and Geneva venture firm that funds single-asset drug companies run by experienced drug hunters. Its cancer companies have included ProfoundBio (bought by Genmab), Kurome Therapeutics and Gadeta.

## Summary

Medicxi has offices in London (25 Great Pulteney Street), Geneva and Jersey (contact page). Its approach is asset-centric: backing focused companies built around one or a few drug candidates, often with partners such as Verily, Novartis and GSK as limited partners. Its news room records a EUR 400 million Medicxi III fund closed in 2019 and a $40 million investment in D3 Bio in 2024. Oncology deals in the news room include Genmab's acquisition of ProfoundBio (antibody-drug conjugates), Kurome Therapeutics' $15 million Series A for kinase inhibitors in haematological cancers, Divide & Conquer (disrupting cell-to-cell communication in cancer), Yukin Therapeutics and Gilead's purchase of the gamma-delta T-cell company Gadeta. Non-oncology exits such as Centessa (Lilly) and Vicebio (Sanofi) dominate recent headlines.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: vc
- HQ: London
- Type: investor
- Website: https://www.medicxi.com/

## Notes

- Founding year not stated on fetched pages and there is no Wikipedia article; omitted. The companies page is rendered client-side.

## Sources

- Official website: https://www.medicxi.com/
- News room: https://www.medicxi.com/news-room
- Contact: https://www.medicxi.com/contact

## Connected records

- companies: [Genmab](https://onco.cc/companies/genmab/), [ProfoundBio](https://onco.cc/companies/profoundbio/)

---
JSON: https://onco.cc/api/v1/entities/medicxi.json